Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
In vitro model of ischemic heart failure using human induced pluripotent stem cell–derived cardiomyocytes
Justin Davis, Ahmad Chouman, Jeffery Creech, Andre Monteiro da Rocha, Daniela Ponce-Balbuena, Eric N. Jimenez Vazquez, Ruthann Nichols, Andrey Lozhkin, Nageswara R. Madamanchi, Katherine F. Campbell, Todd J. Herron
Justin Davis, Ahmad Chouman, Jeffery Creech, Andre Monteiro da Rocha, Daniela Ponce-Balbuena, Eric N. Jimenez Vazquez, Ruthann Nichols, Andrey Lozhkin, Nageswara R. Madamanchi, Katherine F. Campbell, Todd J. Herron
View: Text | PDF
Resource and Technical Advance Cardiology Cell biology

In vitro model of ischemic heart failure using human induced pluripotent stem cell–derived cardiomyocytes

  • Text
  • PDF
Abstract

Human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) have been used extensively to model inherited heart diseases, but hiPSC-CM models of ischemic heart disease are lacking. Here, our objective was to generate an hiPSC-CM model of ischemic heart disease. To this end, hiPSCs were differentiated into functional hiPSC-CMs and then purified using either a simulated ischemia media or by using magnetic antibody-based purification targeting the nonmyocyte population for depletion from the cell population. Flow cytometry analysis confirmed that each purification approach generated hiPSC-CM cultures that had more than 94% cTnT+ cells. After purification, hiPSC-CMs were replated as confluent syncytial monolayers for electrophysiological phenotype analysis and protein expression by Western blotting. The phenotype of metabolic stress–selected hiPSC-CM monolayers recapitulated many of the functional and structural hallmarks of ischemic CMs, including elevated diastolic calcium, diminished calcium transient amplitude, prolonged action potential duration, depolarized resting membrane potential, hypersensitivity to chemotherapy-induced cardiotoxicity, depolarized mitochondrial membrane potential, depressed SERCA2a expression, reduced maximal oxygen consumption rate, and abnormal response to β1-adrenergic receptor stimulation. These findings indicate that metabolic selection of hiPSC-CMs generated cell populations with phenotype similar to what is well known to occur in the setting of ischemic heart failure and thus provide a opportunity for study of human ischemic heart disease.

Authors

Justin Davis, Ahmad Chouman, Jeffery Creech, Andre Monteiro da Rocha, Daniela Ponce-Balbuena, Eric N. Jimenez Vazquez, Ruthann Nichols, Andrey Lozhkin, Nageswara R. Madamanchi, Katherine F. Campbell, Todd J. Herron

×

Figure 8

CDML3 metabolic selection media induces arrhythmia phenotypes in MACS-purified 19-9-11 hiPSC-CM monolayers and antibiotic resistance–purified hiPSC-CMs.

Options: View larger image (or click on image) Download as PowerPoint
CDML3 metabolic selection media induces arrhythmia phenotypes in MACS-pu...
(A) Action potential traces (fluovolt) of hiPSC-CMs maintained in RPMI plus B27 maintenance media. (B and C) CDML3 induced arrhythmia phenotypes observed using voltage sensitive dye. (D) APD30, (E) APD50, and (F) action potential triangulation are greater in CDML3-treated hiPSC-CMs. RPMI plus B27, APD30 = 284.7 ± 27.8 ms; CDML3 APD30 = 309.7 ± 29.0 ms; unpaired t tests, *P < 0.001, n = 94 and n = 95. RPMI APD90 = 823.2 ± 366.1 ms; CDML3 APD90 = 1266.7 ± 499.9 ms; unpaired t test, *P < 0.001. RPMI triangulation = 0.60 ± 0.13; CDML3 triangulation = 0.72 ± 0.12; unpaired t test, *P < 0.001. (G) None of the 94 wells showed spontaneous arrhythmias in RPMI plus B27 monolayers, whereas 24 of 95 monolayers presented with spontaneous arrhythmias in the CDML3-treated group. (H–J) Electrophysiology and calcium flux of iCell2 CMs is affected by maintenance in CDML3 media. APD50 and CaTD50 are prolonged in the CDML3 media–treated monolayers. Calcium transient amplitude of CDML3 media–treated monolayers plated in 96-well plates is reduced compared with RPMI-B27 maintenance media. (K) Seahorse measurement of OCR shows reduced maximal OCR (L) and reduced reserve respiratory capacity (M) in CDML3-treated hiPSC-CM monolayers. hiPSC-CMs, human induced pluripotent stem cell–derived cardiomyocytes; MACS, magnetic-activated cell sorting; OCR, oxygen consumption rate. Unpaired t test, **P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts